Dimerix Ltd (ASX: DXB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Dimerix Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $302.36 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 549.74 million
Earnings per share -0.029
Dividend per share N/A
Year To Date Return 197.56%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Dimerix Ltd (ASX: DXB)
    Latest News

    Woman looks amazed and shocked as she looks at her laptop.
    Share Gainers

    If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!

    The little-known ASX healthcare stock has delivered eye-watering 12-month gains. But how?

    Read more »

    Doctor doing a telemedicine using laptop at a medical clinic
    Healthcare Shares

    2 ASX biotech shares that could be the next Telix Pharmaceuticals

    These ASX biotech shares could become the next Telix Pharmaceuticals. But how?

    Read more »

    four excited doctors with their hands in the air
    Healthcare Shares

    Guess which ASX healthcare stock is rocketing 20% today

    This stock is rising despite raising capital. What's going on?

    Read more »

    a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
    Share Gainers

    Why Dimerix, Evolution, GQG, and Steadfast shares are climbing today

    These ASX shares are ending the week on a high.

    Read more »

    A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
    Healthcare Shares

    This ASX healthcare share has jumped 280% in just two days!

    Shareholders of this healthcare stock will be smiling long into the weekend.

    Read more »

    Rocket powering up and symbolising a rising share price.
    Healthcare Shares

    Guess which ASX healthcare share is rocketing 130% on some big news

    Some big news is getting investors excited on Thursday.

    Read more »

    Two lab technicians wearing white coats discuss results they see on a computer screen.
    Healthcare Shares

    Dimerix (ASX:DXB) share price jumps on COVID study update

    The biopharma specialist is bringing its study to Australia.

    Read more »

    A health worker wearing disposable gloves holds a vial, treating a patient.
    Healthcare Shares

    Dimerix (ASX:DXB) share price soars as boss looks back on 'pivotal' year

    It was a big FY21 for Dimerix. Here's what its CEO has to say about it.

    Read more »

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Share Gainers

    These 3 ASX Healthcare shares have soared over 10% today

    The three healthcare shares are well on the rise today. Read on for more details.

    Read more »

    A group of science or medical professionals cheering good news in the lab.
    Healthcare Shares

    Dimerix (ASX:DXB) share price soars 9% on COVID-19 news

    COVID-19 continues to spread across the globe at pandemic levels.

    Read more »

    A group of science or medical professionals cheering good news in the lab.
    Healthcare Shares

    The Dimerix (ASX:DXB) share price is up 3% on Thursday

    It's a good day on the ASX for the the drug development company

    Read more »

    Share Fallers

    Dimerix (ASX:DXB) share price down 10% after prospectus issued

    Dimerix shares are on the way down after another capital raise was announced

    Read more »

    DXB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Dimerix Ltd

    A clinical stage drug discovery and development company. The operational headquarters of the company are in Melbourne, where Dimerix's lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200

    DXB Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jun 2024 $0.55 $-0.06 -9.84% 4,010,516 $0.61 $0.61 $0.55
    20 Jun 2024 $0.61 $0.05 9.01% 3,305,517 $0.57 $0.62 $0.57
    19 Jun 2024 $0.56 $-0.01 -1.75% 5,779,764 $0.56 $0.59 $0.54
    18 Jun 2024 $0.57 $-0.05 -8.13% 5,806,642 $0.62 $0.65 $0.57
    17 Jun 2024 $0.62 $-0.03 -4.65% 5,580,464 $0.65 $0.67 $0.61
    14 Jun 2024 $0.65 $0.07 12.07% 5,951,005 $0.59 $0.65 $0.58
    13 Jun 2024 $0.58 $-0.03 -4.96% 4,310,242 $0.61 $0.61 $0.57
    12 Jun 2024 $0.61 $0.04 7.14% 8,002,115 $0.56 $0.62 $0.56
    11 Jun 2024 $0.56 $-0.01 -1.74% 4,234,087 $0.58 $0.58 $0.55
    07 Jun 2024 $0.58 $0.03 5.56% 4,754,945 $0.54 $0.58 $0.53
    06 Jun 2024 $0.54 $0.05 10.20% 6,829,790 $0.50 $0.55 $0.50
    05 Jun 2024 $0.49 $-0.01 -2.02% 5,015,974 $0.50 $0.51 $0.48
    04 Jun 2024 $0.50 $-0.01 -1.98% 10,710,031 $0.54 $0.56 $0.50
    03 Jun 2024 $0.51 $0.01 2.02% 5,293,929 $0.51 $0.52 $0.49
    31 May 2024 $0.50 $0.04 8.79% 11,568,195 $0.45 $0.51 $0.44
    30 May 2024 $0.46 $0.06 15.00% 12,106,868 $0.41 $0.47 $0.40
    29 May 2024 $0.40 $0.01 2.56% 6,715,744 $0.40 $0.42 $0.39
    28 May 2024 $0.39 $-0.04 -9.41% 12,974,166 $0.42 $0.42 $0.39
    27 May 2024 $0.43 $0.09 26.47% 21,770,514 $0.38 $0.43 $0.37
    24 May 2024 $0.34 $0.00 0.00% 1,496,856 $0.34 $0.34 $0.33
    23 May 2024 $0.34 $0.00 0.00% 858,762 $0.34 $0.35 $0.34

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    10 Apr 2024 Nina Webster Expiry 25,000 $7,625
    Options expired.
    10 Apr 2024 Sonia Poli Expiry 37,500 $11,437
    Options expired. As per announcement on 03-06-2024
    27 Mar 2024 Nina Webster Buy 33,000 $10,230
    On-market trade.
    26 Mar 2024 Sonia Poli Exercise 12,501 $1,575
    Exercise of options.
    26 Mar 2024 Sonia Poli Issued 12,501 $1,575
    Exercise of options.
    19 Mar 2024 Nina Webster Issued 93,750 $11,812
    Exercise of options.
    19 Mar 2024 Nina Webster Exercise 93,750 $11,812
    Exercise of options.
    01 Dec 2023 Nina Webster Issued 2,052,956 $282,675
    Employee Share Ownership Plan. Black-Scholes valuation
    30 Oct 2023 Nina Webster Expiry 6,351,975 $1,079,835
    Options expired.
    28 Jun 2023 Nina Webster Issued 34,167 $13,666
    Rights issue.
    28 Jun 2023 Sonia Poli Issued 11,334 $4,533
    Rights issue.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Mark P Diamond Non-Executive Director Dec 2023
    --
    Mr Hugh Alsop Non-Executive Director May 2017
    Mr Alsop is an accomplished and commercially focused executive with experience in international business development, partnering, drug development and leadership of scientific teams. Hugh is currently CEO of Kinoxis Therapeutics, a private company developing novel therapeutics for substance use disorders and other neurological conditions. Prior to Kinoxis, Hugh was CEO of venture-backed private company Hatchtech, where he was responsible for several drug development programs for the international markets. Hugh is also a non Executive Director of private companies Servatus Ltd, Eflare Corporation Pty Ltd, Avalyn Australia Pty Ltd, AnaptysBio Pty Ltd and Lassen Therapeutics1 Pty Ltd.
    Ms Nina Webster Chief Executive OfficerManaging Director Aug 2018
    Ms Webster has experience in the pharmaceutical industry, with leadership roles across strategy, commercialisation, intellectual property, scientific and operational aspects of product development.Nina worked in large Pharma, Wyeth Pharmaceuticals (UK). Nina is also a Non-Executive Director of Linear Clinical Research Limited and SYNthesis BioVentures Pty Ltd.
    Dr Sonia Maria Poli Non-Executive Director Jul 2015
    Ms Poli is an accomplished R&D professional with 20 years international experience in large and small pharmaceutical companies. Sonia is currently serving as advisor for several late stage drug development projects approaching market authorization. Sonia was formerly Executive Manager at AC Immune,Nasdaq listed company, and Chief Scientific Officer at Minoryx and Addex Therapeutics and she has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche.
    Mr Clinton Snow Non-Executive Director May 2023
    Mr Snow has 20 years experience as a technology leader with a focus in engineering management, project delivery, risk management and assurance. Clinton is providing advisory services to a family office with multiple Australian biotech investments.
    Mr Hamish George Chief Financial OfficerCompany Secretary May 2019
    -
    Hamish George Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr Peter Fletcher Meurs 35,572,412 9.08%
    Skiptan Pty Ltd <P&M Meurs Family A/C> 29,357,028 7.50%
    Freedom Trader Pty Ltd 9,375,152 2.39%
    Bavaria Bay Pty Ltd 7,316,992 1.87%
    Yodambao Pty Ltd 6,362,603 1.62%
    Mrs Melinda Jane Coates & Mr Andrew Joseph Coates 5,000,000 1.28%
    Mrs Julie Maree Scott 4,425,000 1.13%
    Mr Philip Robert Scott 4,425,000 1.13%
    Mr Andrew Joseph Coates & Mrs Melinda Jane Coates 4,311,500 1.10%
    Mr Richard Stanley De Ravin 4,200,000 1.07%
    Tamer Yigit Property Group Pty Ltd 3,870,000 0.99%
    Mr Taylor Nicholas Green 3,500,000 0.89%
    Mr Anthony Mark Van Der Steeg 3,090,519 0.79%
    Limnos 34 Pty Ltd 3,000,728 0.77%
    Mrs Gwen Murray Pfleger 2,807,984 0.72%
    Rubi Holdings Pty Ltd 2,500,000 0.64%
    Coates Family Office Pty Ltd 2,300,000 0.59%
    Toroha Pty Ltd 2,137,753 0.55%
    Solequest Pty Ltd 2,000,000 0.51%
    Moore Family Nominees Pty Ltd 2,000,000 0.51%
    Citicorp Nominees Pty Limited 1,953,707 0.50%
    Jampaso Pty Ltd 1,778,742 0.45%

    Profile

    since

    Note